Scholar Insight Journal
https://scholarinsightjournal.com/
Volume.4, Issue.4 (Oct-Dec-2026)
Acceptance Date: 02-09-2026

HEC PAKISTAN Y Category
ONLINE - ISSN- 3006-9785
PRINT - ISSN- 3007-245X
Publication Date: 02-11-2026

The Molecular Fountain of Youth: Re-Evaluating Metformin and Geroscience Through the Lens of Medical Humanities

Sajib Kumar Das
MBBS Final Year, Sher-E-Bangla Medical College, Barisal, Bangladesh.
sajib.sajibkumar587@gmail.com
https://orcid.org/0009-0002-4819-312X
Sadia Tabassum Jamy
MBBS Final Year, Sher-E-Bangla Medical College, Barisal, Bangladesh
tabassumsadia865@gmail.com
Preetikana Sarker
MBBS Final Year, Sir Salimullah Medical College, Dhaka, Bangladesh
gourssarker@gmail.com

Abstract

For millennia, human culture framed the desire to transcend aging within mythic, theological, and literary archetypes, ranging from the *Epic of Gilgamesh* to the Faustian bargain. In contemporary medicine, this existential pursuit has shifted to molecular laboratories, where the discipline of geroscience seeks to intervene in fundamental biological mechanisms of decay. Metformin a widely prescribed, low-cost biguanide historically limited to managing type 2 diabetes mellitus—has recently emerged as a primary artifact in this scientific transition. Operating at the boundary between mundane clinical therapeutics and anti-aging bio-transcendence, metformin's repositioning as a geroprotective candidate offers a critical focal point for humanistic inquiry. This paper critically evaluates the biological claims surrounding metformin including AMP-activated protein kinase (AMPK) activation, mechanistic target of rapamycin (mTOR) inhibition, autophagic degradation, chromatin fragment dynamics, and epigenetic biological clocks by embedding them within theoretical frameworks of Medical Humanities, Philosophy of Science, and Bioethics. We analyze how biomedical discourses construct aging either as a natural teleological process or as a treatable pathology, examine the ethical implications of non-human primate research (such as the 40-month cynomolgus monkey trial), and deconstruct the socio-economic paradigm shift proposed by the Targeting Aging with Metformin (TAME) trial framework. By synthesizing empirical literature with critical theory, this study demonstrates how geroprotective science reflects evolving cultural anxieties surrounding mortality, social utility, and the ethics of bodily extension.

Keywords: Metformin, Geroscience, Medical Humanities, Philosophy of Aging, Bioethics, Geroprotection, Technological Somatization, Life Extension

© 2026 Sajib Kumar Das et al.

Scholar Insight Journal
https://scholarinsightjournal.com/
Volume.4, Issue.4 (Oct-Dec-2026)
Acceptance Date: 02-09-2026

HEC PAKISTAN Y Category
ONLINE - ISSN- 3006-9785
PRINT - ISSN- 3007-245X
Publication Date: 02-11-2026

1. Introduction: From Mythic Immortality to Molecular Interventions

Humanity's relationship with aging has always been mediated through narrative, cultural symbol, and existential struggle. Early cultural accounts rarely treated aging as a technical problem to be solved; rather, senescence was understood as an intrinsic component of the cosmological order or a tragic consequence of mortal existence (Baars, 2012). From the Babylonian narrative of Gilgamesh searching for the plant of rejuvenation to the Greek myth of Tithonus—who secured eternal life but failed to request eternal youth—mythology warned against attempting to decouple human identity from biological temporality.

In the twenty-first century, modern geroscience has radically reconfigured this historic relationship. Geroscience posits that aging is not an immutable, teleological horizon, but a plastic biological state driven by interconnected cellular and molecular hallmarks (López-Otín et al., 2023). Rather than addressing age-associated pathologies—such as cardiovascular disease, neurodegeneration, oncogenesis, and frailty—as isolated clinical entities, geroprotective research seeks to intervene directly in the underlying rate of biological aging (Barzilai, 2017).

Within this changing landscape, metformin has assumed a unique status. Originally synthesized from *Galega officinalis* (French lilac) and approved decades ago for managing type 2 diabetes mellitus, metformin is an inexpensive, ubiquitous pharmacological agent with a long-established safety profile (Aedh et al., 2026; Manneh et al., 2026). However, recent preclinical findings, non-human primate studies, and observational epidemiology have elevated metformin from a mundane metabolic treatment to a potential "geroprotective" drug (Yang et al., 2024).

This transition raises questions that extend far beyond molecular biology. How does a metabolic medication become imbued with cultural ideals of longevity? What happens to the human understanding of disease when physiological aging itself is framed as a target for pharmacological intervention? This article applies a critical humanities lens to the scientific literature on metformin, exploring the philosophical, socio-ethical, and epistemological dimensions of the contemporary anti-aging paradigm.

2. Theoretical and Epistemological Frameworks

To evaluate the ongoing repositioning of metformin within geroscience, this study integrates three critical methodologies within the Arts and Humanities:

1. **Medical Humanities and Narrative Medicine:** Examining how scientific texts construct the narrative arc of biological decay, transforming physiological changes into metaphors of "maintenance," "damage," or "rejuvenation" (Charon, 2006).

© 2026 Sajib Kumar Das et al.

HEC PAKISTAN Y Category
ONLINE - ISSN- 3006-9785
PRINT - ISSN- 3007-245X
Publication Date: 02-11-2026

2. **Philosophy of Science and Bioethics:** Investigating the evidentiary standards, epistemic uncertainty, and moral boundary-work involved in shifting aging from a "natural process" to a "pathological target" (Caplan, 2005; Social Philosophy and Policy Foundation, 2007).
3. **Sociology of the Body and Cultural Studies:** Analyzing how geroprotective technologies intersect with neoliberal expectations of personal health preservation, economic utility in late life, and the commodification of bodily longevity (Rose, 2007).

3. Hermeneutic Analysis of Molecular Pathways: Cellular Mechanics as Cultural Metaphors

Biomedical literature describes metformin's potential geroprotective activity through several interconnected intracellular networks. Examining these pathways through humanistic lenses reveals how biological processes are conceptualized using cultural metaphors of order, economy, and restraint.

3.1 AMPK Signaling and the Ethics of Ascetic Restraint

AMP-activated protein kinase (AMPK) functions as the master cellular energy sensor, responding to metabolic stress by suppressing anabolic growth pathways and activating catabolic repair mechanisms (Aedh et al., 2026; Manneh et al., 2026). When metformin activates AMPK, it shifts cellular resources away from rapid growth and toward maintenance and energy conservation.

Philosophically, this biological mechanism functions as a biochemical analog to traditional virtues of asceticism, temperance, and moderation. From Stoic philosophy (e.g., Seneca's writing on frugality) to monastic traditions, cultures have linked physical restraint to bodily endurance and spiritual clarity. In modern scientific discourse, AMPK activation translates this moral imperative of "restraint" into a metabolic command, suggesting that biological preservation requires cells to enter a state of disciplined resource allocation.

3.2 mTOR Inhibition, Autophagy, and the Aesthetics of Renewal

The mechanistic target of rapamycin (mTOR) pathway regulates nutrient sensing, cell proliferation, and protein synthesis. Hyperactivation of mTOR accelerates cellular aging, whereas its suppression promotes autophagy—the cellular process of degrading damaged organelles and misfolded proteins (Manneh et al., 2026). Metformin inhibits mTOR signaling through both AMPK-dependent and independent pathways (Aedh et al., 2026).

Autophagy represents a biological mechanism of internal self-cleansing. Within cultural theory and art history, aesthetic renewal requires the systematic clearing away of accumulated debris;

© 2026 Sajib Kumar Das et al.

HEC PAKISTAN Y Category
ONLINE - ISSN- 3006-9785
PRINT - ISSN- 3007-245X
Publication Date: 02-11-2026

decay must be actively processed for harmony to be maintained. The geroprotective focus on autophagic clearance illustrates a broader cultural motif: longevity is achieved not merely by acquiring new vital capacity, but by clearing structural waste.

3.3 Cellular Senescence, SASP, and the Rhetoric of Internal Disruption


Cellular senescence occurs when damaged cells undergo irreversible growth arrest while remaining metabolically active, secreting pro-inflammatory cytokines, chemokines, and matrix metalloproteinases—collectively termed the Senescence-Associated Secretory Phenotype (SASP) (Aedh et al., 2026; Kumazawa et al., 2026). Accumulation of senescent cells leads to chronic tissue inflammation ("inflammaging") and functional decline.

Kumazawa et al. (2026) demonstrated that metformin reduces age-associated inflammatory signaling by limiting the formation of cytoplasmic chromatin fragments through an AMPK-dependent mechanism, degraded via ALIX-mediated autophagy. This suppresses the activation of the cGAS–STING inflammatory pathway in aging mice models (Kumazawa et al., 2026).

In socio-political terms, the senescent cell functions within scientific narrative as an "internal disruptor"—a cell that no longer contributes to tissue utility yet continuously disrupts its local cellular community through inflammatory signals. Metformin’s reported capacity to suppress chromatin fragment egress and SASP release reflects a narrative of restoring cellular order and quelling micro-level "social unrest" within the organismic body.


4. Primate Studies and Epigenetic Clocks: Biological Time vs. Existential Time

A major development in geroprotective research was a 40-month longitudinal study on adult male cynomolgus monkeys treated with metformin (Yang et al., 2024). The authors reported that metformin decelerated age-related biological changes across physiological, transcriptomic, proteomic, metabolomic, and neuro-epigenetic indicators (Yang et al., 2024).



© 2026 Sajib Kumar Das et al.

HEC PAKISTAN Y Category
ONLINE - ISSN- 3006-9785
PRINT - ISSN- 3007-245X
Publication Date: 02-11-2026



4.1 Epigenetic Clocks and the Quantified Self

Epigenetic clocks measure DNA methylation patterns across specific genomic loci to estimate an organism's "biological age," which can diverge from its chronological age (Yang et al., 2024). The development of these molecular biomarkers represents a fundamental shift in how human culture quantifies aging:

- **Chronological Age:** Linear, historical, and unyielding.
- **Biological Age:** Plastic, quantifiable, and potentially modifiable through pharmacological means.

From a philosophical perspective, biological aging clocks redefine human temporality. Aging is no longer measured solely by the movement of calendar time, but by internal molecular indicators. This shift risks reducing the lived human experience of time to measurable somatic metrics, accelerating what sociologists call the "quantified self" paradigm (Rose, 2007).

4.2 Non-Human Primates as Bioethical Mirrors

Because cynomolgus monkeys share high genetic, physiological, and cognitive similarities with humans, the monkey trial by Yang et al. (2024) carries profound symbolic weight. Primates serve as biological and moral proxies for humanity. Demonstrating that a pharmaceutical agent can slow multi-systemic aging indicators in primates destabilizes the long-held boundary between immutable natural law and alterable physiology. However, as bioethicists caution, shifting a molecular biomarker in a non-human primate does not automatically demonstrate extended human healthspan or meaningful existential benefit (Caplan, 2005; Keys et al., 2025).

5. Epistemic Uncertainty and the Socio-Ethical Architecture of TAME

5.1 Observational Fallacies and Epistemic Risk

While observational human studies have linked metformin exposure to reduced incidence of age-related comorbidities and lowered all-cause mortality in diabetic populations (Wang et al., 2017), these findings suffer from significant epistemic limitations. As critical reviewers emphasize, observational data cannot establish causality due to residual confounding, indication bias, and healthy-user effects (Keys et al., 2025). Systematic analyses across lower organism models (e.g., *C. elegans* and rodents) further demonstrate high heterogeneity,

© 2026 Sajib Kumar Das et al.

HEC PAKISTAN Y Category
ONLINE - ISSN- 3006-9785
PRINT - ISSN- 3007-245X
Publication Date: 02-11-2026

showing that lifespan extension depends heavily on genetic background, sex, dosage, and intervention timing (Parish et al., 2022).

The eagerness to interpret correlational diabetic data as definitive proof of human life extension reflects a widespread cultural bias: the desire to find simple, accessible solutions to complex biological problems.

5.2 The TAME Framework: Re-Defining Disease in Modern Bio-Economy

The *Targeting Aging with Metformin* (TAME) trial initiative led by Barzilai (2017) represents a major structural shift in clinical medicine. TAME proposes to evaluate whether metformin can delay a composite endpoint of major age-related diseases—including myocardial infarction, stroke, specific cancers, mild cognitive impairment/dementia, and all-cause mortality—in non-diabetic individuals aged 65–79 (Barzilai, 2017).

Traditional Medical Model:
[Disease A: Cancer] ----------> [Treatment A]
[Disease B: CVD] ----------> [Treatment B]
[Disease C: Dementia] --------> [Treatment C]
Geroscience / TAME Paradigm:
+---> [Delays Cancer]
[Metformin / Geroprotector] ---+---> [Delays CVD]
+---> [Delays Dementia]

This model challenges the traditional disease-specific structure of clinical medicine:

1. **From Pathology-Specific to Systemic:** Instead of treating diseases serially as they emerge, geroscience targets the shared biological driver (aging itself).
2. **Medicalization of Aging:** By framing senescence as an intervention target, TAME implicitly redefines normal biological aging as a treatable condition, blurring the traditional boundary between therapy and enhancement (Caplan, 2005).
3. **Economic Utility and Neoliberal Ageing:** In aging societies, delaying disease onset by even a few years promises to reduce public health expenditures. However, this creates a social narrative where individuals are increasingly expected to manage their somatic decline to remain productive economic participants (Rose, 2007).

6. Clinical Paradoxes, Safety, and Existential Boundaries

Despite enthusiasm within longevity communities, metformin presents clinical paradoxes that underscore the complexity of human biology. Han et al. (2026) noted that while metformin regulates metabolic indicators, long-term use can blunt muscle hypertrophic adaptations to

© 2026 Sajib Kumar Das et al.

HEC PAKISTAN Y Category
ONLINE - ISSN- 3006-9785
PRINT - ISSN- 3007-245X
Publication Date: 02-11-2026

resistance exercise in older adults and carries risks of vitamin B12 deficiency, renal strain, and gastrointestinal intolerance (Han et al., 2026; Keys et al., 2025).

This clinical paradox highlights an essential bioethical lesson: biological systems operate through delicate trade-offs rather than linear improvements. The pursuit of longevity through pharmacological means risks producing unintended physiological side effects, echoing historical warnings against uncritical technological interventions in natural systems.

7. Conclusion: Beyond the Pharmacological Fountain of Youth

Metformin has evolved from a routine metabolic drug into a central cultural artifact in the modern geroscience movement. As demonstrated in this narrative review, its potential geroprotective properties operate at the intersection of complex biological pathways—including AMPK activation, mTOR suppression, autophagic clearing, and SASP attenuation—and fundamental human questions regarding time, decay, and health.

While preclinical experiments and non-human primate studies offer compelling mechanistic rationale, definitive randomized clinical evidence establishing that metformin extends healthy human lifespan remains absent (Keys et al., 2025; Parish et al., 2022). Metformin should therefore be understood as a promising geroprotective candidate rather than a validated anti-aging therapy.

Ultimately, the debate surrounding metformin reflects humanity's ongoing attempt to re-imagine the boundaries of bodily existence. As medicine continues to explore the biology of aging, humanistic analysis remains essential to ensure that the pursuit of a longer life is guided not only by molecular metrics, but by a thoughtful commitment to human dignity, bioethical responsibility, and equitable health outcomes.

© 2026 Sajib Kumar Das et al.

HEC PAKISTAN Y Category
ONLINE - ISSN- 3006-9785
PRINT - ISSN- 3007-245X
Publication Date: 02-11-2026

References

Aedh, A. I., Al-Kuraishy, H. M., Shokr, M. M., Alruwaili, M., & Batiha, G. E. (2026). Concept and connotation of the geroprotective and anti-aging effects of metformin: From AMPK activation to SASP suppression. *Molecular and Cellular Endocrinology*, *618*, Article 112802. https://doi.org/10.1016/j.mce.2026.112802

Baars, J. (2012). *Aging and the art of living*. Johns Hopkins University Press.

Barzilai, N. (2017). Targeting aging with metformin (TAME). *Innovation in Aging*, *1*(Suppl 1), 743. https://doi.org/10.1093/geroni/igx004.2682

Caplan, A. L. (2005). Anti-aging science: Ethical, conceptual, and policy issues. *Studies in History and Philosophy of Science Part C: Studies in History and Philosophy of Biological and Biomedical Sciences*, *36*(2), 287–297. https://doi.org/10.1016/j.shpsc.2005.03.005

Charon, R. (2006). *Narrative medicine: Honoring the stories of illness*. Oxford University Press.

Han, S. Y., Yadav, M. K., & Wang, J. H. (2026). Metformin for longevity and sarcopenia: A therapeutic paradox in aging. *Biomedicines*, *14*(2), Article 376. https://doi.org/10.3390/biomedicines14020376

Keys, M. T., Smith, R. J., & Taylor, L. N. (2025). Emerging uncertainty on the anti-aging potential of metformin. *Ageing Research Reviews*, *111*, Article 102817. https://doi.org/10.1016/j.arr.2025.102817

Kumazawa, T., Xu, Y., Wang, Y., Lee, J. W., O'Brien, T. C., Ho, C. K., & Zhang, L. (2026). Metformin inhibits nuclear egress of chromatin fragments in senescence and aging. *Nature Aging*, *6*(2), 303–315. https://doi.org/10.1038/s43587-025-01048-0

López-Otín, C., Blasco, M. A., Partridge, L., Serrano, M., & Kroemer, G. (2023). Hallmarks of aging: An expanding universe. *Cell*, *186*(2), 243–278. https://doi.org/10.1016/j.cell.2022.11.001

Manneh, J., Alasmar, M., & El Hajj, N. (2026). Metformin at the convergence of aging and longevity. *Aging*, *18*(1), 970–990. https://doi.org/10.18632/aging.206407

Martin-Montalvo, A., Mercken, E. M., Mitchell, S. J., Palacios, H. H., Mote, P. L., Scheibye-Knudsen, M., Gomez-Cabrera, M. C., Viña, J., Roth, G. S., de Cabo, R., & Bernier, M. (2013). Metformin improves healthspan and lifespan in mice. *Nature Communications*, *4*, Article 2192. https://doi.org/10.1038/ncomms3192

© 2026 Sajib Kumar Das et al.

HEC PAKISTAN Y Category
ONLINE - ISSN- 3006-9785
PRINT - ISSN- 3007-245X
Publication Date: 02-11-2026

Parish, A. J., Lord, S. R., & Turner, N. (2022). Metformin has heterogeneous effects on model organism lifespans and is beneficial when started at an early age in *Caenorhabditis elegans*: A systematic review and meta-analysis. *Aging Cell*, *21*(12), Article e13733. https://doi.org/10.1111/acel.13733

Rose, N. (2007). *The politics of life itself: Biomedicine, power, and subjectivity in the twenty-first century*. Princeton University Press.

Social Philosophy and Policy Foundation. (2007). *Personal identity and bioethics*. Cambridge University Press.

Wang, C. P., Lorenzo, C., Habib, S. L., Jo, B., & Espinoza, S. E. (2017). Differential effects of metformin on age related comorbidities in older men with type 2 diabetes. *Journal of Diabetes and Its Complications*, *31*(4), 679–686. https://doi.org/10.1016/j.jdiacomp.2016.12.001

Yang, Y., Lu, X., Liu, N., Ma, S., Zhang, H., Zhang, Z., Yang, K., Jiang, M., Zheng, Z., Jiao, L., Hu, J., Li, Y., Yang, F., Pang, Y., Zhao, Y., & Liu, G. H. (2024). Metformin decelerates aging clock in male monkeys. *Cell*, *187*(22), 6358–6378.e29. https://doi.org/10.1016/j.cell.2024.08.021

© 2026 Sajib Kumar Das et al.